HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced significant long-term improvement in symptoms of benign prostatic hyperplasia (BPH) in men treated with the Company’s investigational drug NX-1207 in a newly completed clinical study.